BIIB Financial Facts
Total cost and expenses: 1.53BDiluted earnings per share attributable to Biogen Idec Inc.: 219.4M
See Full Income Statement
Accumulated other comprehensive income (loss): -300.9M
Preferred stock, par value $0.001 per share: 0
See Full Balance Sheet
Biogen Idec Inc. (BIIB) Earnings
|
Expand Research on BIIB
| Next EPS Date | 10/30/26 *Est. | EPS Growth Rate | -34.2% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +20.5% | Revenue Growth Rate | +5.4% *Last Qtr. |
| Average % Move 1-Wk after EPS | +3.5% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7/29/26 | Q226 | $3.60 | $3.17 | +$0.43 | $2.74B | $2.43B | = |  | | Details | |
| 4/29/26 | Q126 | $3.57 | $2.95 | +$0.62 | $2.48B | $2.25B | = | | | Details | |
| 2/6/26 | Q425 | $1.99 | $1.61 | +$0.38 | $2.28B | $2.21B | = | | | Details | |
| 10/30/25 | Q325 | $4.81 | $3.88 | +$0.93 | $2.53B | $2.34B | = | | | Details | |
| 7/31/25 | Q225 | $5.47 | $3.99 | +$1.48 | $2.6B | $2.32B | = | | | Details | |
| 5/1/25 | Q125 | $3.02 | $2.96 | +$0.06 | $2.43B | $2.23B | = | | | Details | |
| 2/12/25 | Q424 | $3.44 | $3.41 | +$0.03 | $2.45B | $2.41B | = | | | Details | |
| 10/30/24 | Q324 | $4.08 | $3.77 | +$0.31 | $2.47B | $2.43B | = | | | Details |
